- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Safety AND Alzheimer Disease AND Healthy.
Displaying page 1 of 2.
EudraCT Number: 2018-001071-20 | Sponsor Protocol Number: NSC18001 | Start Date*: 2018-09-19 | ||||||||||||||||
Sponsor Name:Pharmatrophix Inc | ||||||||||||||||||
Full Title: A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy ... | ||||||||||||||||||
Medical condition: Mild to moderate Alzheimer's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000870-20 | Sponsor Protocol Number: IMU-AD-001 | Start Date*: 2015-05-27 | |||||||||||
Sponsor Name:Immungenetics AG | |||||||||||||
Full Title: An open-label, multicenter, controlled pharmaco-dynamic clinical trial to explore the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with early-to-mild dementia due to Alzheimer... | |||||||||||||
Medical condition: Newly diagnosed early-to-mild dementia due to Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005576-18 | Sponsor Protocol Number: CCNP520X2102 | Start Date*: 2015-08-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly su... | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000943-29 | Sponsor Protocol Number: BP28248 | Start Date*: 2012-11-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER’S DISEASE THERAPY IN... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012569-79 | Sponsor Protocol Number: BAY94-9172/14595 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when com... | |||||||||||||
Medical condition: Detection/Exclusion of cerebral ß-amyloid. To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003552-36 | Sponsor Protocol Number: COG0202 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease | |||||||||||||
Medical condition: Mild to Moderate Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002326-27 | Sponsor Protocol Number: COG0201 | Start Date*: 2022-09-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023513-64 | Sponsor Protocol Number: GE-067-015 | Start Date*: 2011-01-05 | |||||||||||
Sponsor Name:GE Healthcare Ltd. and its Affiliates | |||||||||||||
Full Title: A Single-Arm Open-Label Multi-Center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40 | |||||||||||||
Medical condition: Healthy volunteers (the absence of brain amyloid will be studied; amyloid is present in Alzheimer's disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) GB (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002256-42 | Sponsor Protocol Number: 311741 | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/excl... | |||||||||||||
Medical condition: Probable Alzheimer Disease patients compared to Healthy Volunteers. The clinical diagnosis - in Part A made by the investigator, in Part B established by an independent consensus panel of experts... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004918-17 | Sponsor Protocol Number: A2501046 | Start Date*: 2005-04-01 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) CZ (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004890-93 | Sponsor Protocol Number: E2020-G000-328 | Start Date*: 2008-07-04 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: E2020-G000-328 Open Label Extension Study of 23mg Donepezil SR in Patients with Moderate to Severe Alzheimer's Disease. | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) ES (Completed) GB (Completed) AT (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008555-41 | Sponsor Protocol Number: INSULA | Start Date*: 2011-05-26 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Essen | ||||||||||||||||||
Full Title: Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA) | ||||||||||||||||||
Medical condition: Early Alzheimer´s dementia (eAD), type 2 diabetes mellitus with amnestic mild cognitive impairment (T2D-aMCI), healthy controls (Co) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012394-35 | Sponsor Protocol Number: CCAD106A2203 | Start Date*: 2010-03-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer’s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon... | |||||||||||||
Medical condition: Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004888-54 | Sponsor Protocol Number: E2020-G000-326 | Start Date*: 2007-12-07 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) LT (Completed) ES (Completed) AT (Completed) DK (Completed) SE (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000763-41 | Sponsor Protocol Number: FBB-FAD-2014 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA | |||||||||||||
Full Title: Study of genetic Alzheimer?s disease mutation carriers in preclinical stages of the disease: 18F-Florbetaben Positron Emission Tomography study. | |||||||||||||
Medical condition: Healthy voulnteers carrying a mutation in at least one of the following genes: PSEN1, PSEN2 or APP. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003891-11 | Sponsor Protocol Number: LMT-01-02-18 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:Life Molecular Imaging SA | |||||||||||||
Full Title: An Open Label, Single Center Study, to evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau deposition in the brains of subjects with amnestic mild cog... | |||||||||||||
Medical condition: Alzheimer's Disease Amnestic Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002614-10 | Sponsor Protocol Number: 10112 | Start Date*: 2005-05-17 |
Sponsor Name:Lundbeck Limited | ||
Full Title: A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease | ||
Medical condition: Probable Alzheimer's Disease of moderate severity. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002159-24 | Sponsor Protocol Number: 54861911ALZ2002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheime... | |||||||||||||
Medical condition: Early Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004656-22 | Sponsor Protocol Number: IIBSP-THK-2015-77 | Start Date*: 2017-10-10 |
Sponsor Name:Institut de Recerca HSCSP | ||
Full Title: Pilot study of the [18F]THK-5351 positron emission tomography (PET) tracer in different tauopathies. | ||
Medical condition: Taupatías | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-000163-89 | Sponsor Protocol Number: COG0104 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a... | |||||||||||||
Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
